J. Stevenson

发表

A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.

Timothy Zhu, Joseph S Friedberg, Eli Glatstein, 2003, The Annals of thoracic surgery.

Clinical Pharmacokinetics and Administration of Established Platinum Drugs

Steven W. Johnson, P. O'dwyer, J. Stevenson, 2012, Drugs.

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

D. Heitjan, L. Montaner, E. Papasavvas, 2013, Oncoimmunology.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

Sharyn I. Katz, C. Simone, D. Heitjan, 2016, Clinical Cancer Research.

A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.

S. Hahn, J. Tepper, P. Deutsch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin

K. Flaherty, M. Rosen, M. Schnall, 2005, Clinical Cancer Research.

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days

P. O'dwyer, D. Vaughn, J. Stevenson, 2004, British Journal of Cancer.

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Gary W Procop, Jame Abraham, A. Khorana, 2015, Journal of the National Cancer Institute.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

D. Ettinger, L. Chirieac, R. Govindan, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Improving the Management of Patients With Low-Risk Neutropenic Fever at the Cleveland Clinic Taussig Cancer Institute.

Barbara Tripp, J. Stevenson, B. Estfan, 2017, Journal of oncology practice.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

A PILOT AND FEASIBILITY CLINICAL TRIAL EVALUATING IMMUNO-GENE THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) USING INTRAPLEURAL DELIVERY OF ADENOVIRUS- INTERFERON-ALPHA (Ad.hIFN-α2b) IN COMBINATION WITH HIGH-DOSE CELECOXIB AND SYSTEMIC CHEMOTHERAPY

Sharyn I. Katz, C. Simone, D. Heitjan, 2016 .

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

S. Armato, P. Jänne, Helen X. Chen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Non – Small Cell Lung Cancer, Version 3.2022

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022 .

Irinotecan and UFT/leucovorin in patients with advanced cancers.

D. Haller, P. O'dwyer, J. Stevenson, 2000, Oncology.

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.

P. O'dwyer, K. Yao, J. Stevenson, 1998, European journal of cancer.

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

D. Kerr, K. Flaherty, P. O'dwyer, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.

D. Haller, P. O'dwyer, J. Gallo, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

R. Camidge, B. Kavanagh, H. Borghaei, 2019, Cancer treatment and research communications.

Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience

J. Shrager, J. Cooper, C. Langer, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

J. Shrager, L. Kaiser, J. Stevenson, 2004, The Journal of thoracic and cardiovascular surgery.

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

K. Flaherty, P. O'dwyer, J. Stevenson, 2004, Cancer Chemotherapy and Pharmacology.

Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer

K. Flaherty, D. Haller, P. O'dwyer, 2003, Cancer.

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

P B Laub, S. Conway, P. O'dwyer, 2005, British Journal of Cancer.

Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy

M. Socinski, T. Stinchcombe, Carrie Lee, 2020, Cancer.

Reducing xerostomia through advanced technology

J. Stevenson, 2011 .

Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.

T. J. Robnett, S. Hahn, J. Stevenson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive‐Stage Small Cell Lung Cancer (SCLC)

A. Wozniak, B. Halmos, S. Gadgeel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib approval for NSCLC brings EGFR TKI story full circle.

J. Stevenson, 2014, The Journal of community and supportive oncology.

LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

L. Sequist, H. Borghaei, S. Jalal, 2017 .

associations with pathologic response advanced stage III non-small cell lung carcinoma: Long-term results and Two commonly used neoadjuvant chemoradiotherapy regimens for locally

J. Shrager, J. Stevenson, M. Machtay, 2013 .

Impact of Socioeconomic Factors on Overall Survival in SCLC

N. Pennell, J. Stevenson, K. Tullio, 2022, JTO clinical and research reports.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non–Small Cell Lung Cancer Receiving Sequential Treatment

C. Simone, C. Langer, R. Rengan, 2016, American journal of clinical oncology.

24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

L. Sequist, H. Borghaei, S. Jalal, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

M. Socinski, A. Patnaik, S. Gadgeel, 2015 .

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

L. Sequist, H. Borghaei, A. Patnaik, 2015 .

Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.

P. Mazzone, V. Velcheti, N. Pennell, 2017 .

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

V. Velcheti, G. Videtic, Christopher A. Lemmon, 2022, JTO clinical and research reports.

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

D. Haller, P. O'dwyer, D. Vaughn, 2001, Cancer.

Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

L. Sequist, H. Borghaei, S. Jalal, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antisense therapeutics: lessons from early clinical trials

K. Flaherty, P. O'dwyer, J. Stevenson, 2001, Current opinion in oncology.

Adjuvant radiotherapy for completely resected stage 2 thymoma

S. Singhal, J. Metz, J. Cooper, 2011, Cancer.

Reducing Unplanned Medical Oncology Readmissions by Improving Outpatient Care Transitions: A Process Improvement Project at the Cleveland Clinic.

A. Khorana, M. Kalaycio, R. Lagman, 2016, Journal of oncology practice.

Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute.

V. Velcheti, N. Pennell, J. Stevenson, 2016, Journal of oncology practice.

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.

C. Langer, M. Corradetti, N. Mitra, 2011, International journal of radiation oncology, biology, physics.

Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

Steven E. Schild, Renato Martins, Billy W. Loo, 2017 .

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Weijing Sun, Daniel G Haller, Mark Rosen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

L. Grochow, L. Paz-Ares, P. O'dwyer, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

P. O'dwyer, K. Yao, B. Monia, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy of advanced colorectal cancer.

P. O'dwyer, J. Stevenson, James P. Stevenson, 1998, Cancer treatment and research.

c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

P. O'dwyer, K. Yao, B. Monia, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.

K. Schalper, V. Velcheti, S. Mukhopadhyay, 2017, JCO precision oncology.

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Renato Martins, Thomas J Dilling, Steven E Schild, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Current issues in malignant pleural mesothelioma evaluation and management.

J. Stevenson, Jing Ai, 2014, The oncologist.

Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Keith Cengel, Joseph S Friedberg, Eli Glatstein, 2012, The Annals of thoracic surgery.

A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer

E. Rosato, J. Tepper, P. Deutsch, 2004, Clinical Cancer Research.

Programmed Cell Death 1 ( PD-1 ) Ligand ( PD-L 1 ) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1 / PD-L 1 Axis Inhibitors : A Systematic Review and Meta-Analysis

K. Schalper, V. Velcheti, S. Mukhopadhyay, 2017 .

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of Pennsylvania

J. Shults, J. Stevenson, M. L. Veronese, 2005, Cancer investigation.

Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.

S. Hahn, K. Cengel, R. Mick, 2011, The Annals of thoracic surgery.

Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread.

Timothy Zhu, Theresa M Busch, Andreea Dimofte, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

D. Ettinger, L. Chirieac, R. Govindan, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience.

G. T. Budd, A. Khorana, P. Funchain, 2018, JCO precision oncology.

The Clinical Development of Lurtotecan

K. Flaherty, P. O'dwyer, C. Twelves, 2005 .

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients

V. Velcheti, T. Panchabhai, N. Pennell, 2018, PloS one.

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.

C. Thorn, D. Haller, P. O'dwyer, 2004, European journal of cancer.

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.

L. Kluijtmans, D. Haller, P. O'dwyer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Renato Martins, Joe Y. Chang, Thomas J Dilling, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

S. Ramalingam, A. Argiris, J. Schiller, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized trial of carboplatin , paclitaxel , bevacizumab with or without cixutumumab ( IMCA 12 ) in patients with advanced non-squamous , non-small-cell lung cancer : a trial of the ECOG-ACRIN Cancer Research Group ( E 3508 )

S. Ramalingam, A. Argiris, J. Schiller, 2017 .

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.

C. Simone, S. Hahn, A. Maity, 2019, JAMA oncology.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2019, Lung cancer.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

L. Sequist, H. Borghaei, A. Patnaik, 2018, Lung cancer.

Analysis of clonality using X‐linked polymorphisms in a patient with multiple myeloma and myelofibrosis

J. Stevenson, S. Schuster, R. Schwarting, 1998, American journal of hematology.

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death‐Ligand 1 Inhibitors in Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Trials

P. Mazzone, V. Velcheti, N. Pennell, 2017, Chest.

Safety and Efficacy of PD‐1/PD‐L1 Inhibitors in Treatment‐Naive and Chemotherapy‐Refractory Patients With Non–Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis

V. Velcheti, N. Pennell, S. Rakshit, 2018, Clinical lung cancer.

Mechanisms of hypertension associated with BAY 43-9006.

K. Flaherty, R. Townsend, P. O'dwyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.

T. Hamblin, J. Stevenson, P. Palmer, 1993, British Journal of Cancer.

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.

P. O'dwyer, D. Vaughn, L. Schuchter, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

M. Morgan, K. Flaherty, P. O'dwyer, 2005, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.

D. Haller, P. O'dwyer, D. Vaughn, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Photodynamic therapy for the treatment of non-small cell lung cancer.

Charles B Simone, Keith A Cengel, Joseph S Friedberg, 2012, Journal of thoracic disease.

Phase I C linical a nd P harmacogenetic T rial o f I rinotecan and R altitrexed A dministered E very 2 1 D ays t o P atients With C ancer

D. Haller, J. Stevenson, A. Whitehead, 2001 .

New Strategies in Non–Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease

S. Hahn, A. Maity, R. Rengan, 2011, Clinical Cancer Research.

Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial

Steven W. Johnson, P. O'dwyer, I. Vasilevskaya, 2004 .

Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.

Nandita Mitra, Jarod Finlay, Eli Glatstein, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response

M. Rosen, S. Hahn, A. Maity, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.

C. Langer, J. Kucharczuk, N. Mitra, 2012, International journal of radiation oncology, biology, physics.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

K. Flaherty, S. Hahn, P. O'dwyer, 2003, Cancer Chemotherapy and Pharmacology.

Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer

Nandita Mitra, Charles B Simone, Daniel A Pryma, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

J. Stevenson, A. Azzouqa, 2016, OncoTargets and therapy.

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

L. Sequist, H. Borghaei, A. Patnaik, 2016 .

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies

K. Flaherty, D. Haller, P. O'dwyer, 2004, Cancer Chemotherapy and Pharmacology.

Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer

J. Stevenson, A. Hageboutros, C. Dalsania, 2007 .

Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab.

V. Velcheti, N. Pennell, P. Elson, 2017 .

A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.

J. Stevenson, S. Kunte, 2020, Clinical lung cancer.